Latest data shows the largest indicative borrow rate increases among liquid option names include: NEWSMAX INC (NMAX) 328.49% +45.34, ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 7.32%, which has investors questioning if this is right time to buy.

Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 12.39%, which has investors questioning if this is right time ...

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms ...

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms, Lexicon ...

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual ...

According to TipRanks.com, Risinger is a 5-star analyst with an average return of 8.5% and a 54.1% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Structure ...

Charles Schwab Investment Management Inc. lowered its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 16.0% during the 4th quarter, Holdings Channel.com reports.

In November, Lexicon revealed that the Phase 2b trial completed enrollment. I rated LXRX a “Sell.” The stock has since fallen 68% (even with today’s gains). The following article revisits ...